Printer Friendly

OXiGENE REPORTS PILOT STUDY DATA FOR TUMOR SENSITIZER: ADJUNCT THERAPY FOR SQUAMOUS CELL CARCINOMA OF THE LUNG

 NEW YORK, Nov. 8 /PRNewswire/ -- OXiGENE Inc. (NASDAQ: OXGN) today announced that it has completed an interim analysis of a non-randomized, investigator initiated clinical trial designed to evaluate the toxicity and efficacy of the company's chemo/radiation sensitizer, Sensamide(TM), a unique formulation of the synthetic compound metoclopramide.
 Twenty-five patients with highly fatal, inoperable squamous cell carcinoma of the lung were studied at the University of Lund, Sweden, in two groups. Fourteen patients received conventional radiation therapy combined with Sensamide and 11 patients received only the radiation therapy. Those receiving both radiation and Sensamide survived an average of 395 days, almost double the survival of those receiving radiation alone.
 "These trial results, though based on a small number of patients, are statistically significant due to the almost 100 percent increase in average survival," said Ronald W. Pero, Ph.D., OXiGENE's chief scientific officer. "We believe Sensamide can increase tumor sensitivity to radiation, and can improve conventional radiotherapy by reducing the dosage levels currently used for such treatments," he added.
 OXiGENE has initiated recruitment of 226 patients for a Phase II/III clinical trial in Sweden. The trial is being conducted under a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application.
 Tumor response and survival rates are clinical end points required by the FDA to evaluate the efficacy of Sensamide as an enhancer of radiotherapy. The company believes existing FDA guidelines provide for expedited review and approval based on tumor response.
 Sensamide works by inhibiting DNA repair in tumor cells, thus allowing radiotherapy to be more effective. OXiGENE is engaged in the design and development of drugs based on proprietary technology which involves the inhibition, measurement and stimulation of the body's cellular DNA repair process, specifically related to the enhancement of radiation and chemotherapy and for the prevention of cancer and aging disorders.
 -0- 11/8/93
 /CONTACT: Lisa Powell of OXiGENE, 212-421-0001; or Mark Brand or Kimberly Kraemer of Pondel Parsons and Wilkinson, 310-207-9300/
 (OXGN)


CO: OXiGENE Inc. ST: New York IN: MTC SU:

EH-JB -- LA001 -- 1523 11/08/93 06:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 8, 1993
Words:347
Previous Article:COMSHARE INTRODUCES COMMANDER FDC 2.0
Next Article:INCO HOMES CORP. ENTERS ARIZONA HOUSING MARKET -- SOUTHERN CALIFORNIA HOME BUILDER TAKES SUCCESSFUL ENTRY LEVEL STRATEGY TO PHOENIX
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters